Turkey Aims To Bargain With Drug Firms To Ease Costs And Shortages
This article was originally published in PharmAsia News
Turkey’s latest plan to ease shortages of mainly imported drugs for oncology and other chronic diseases while keeping a lid on reimbursement costs is to strike bargains with individual firms. But industry analysts are skeptical that systemic problems linked to exchange rate terms and growing demand will be solved by a new draft regulation allowing the Social Security Institution of Turkey, or SGK, to reach such deals.
You may also be interested in...
Growth prospects for Turkey’s medical technology market are significant, but local companies have complained about public policies that are harmful to business and about the ongoing crisis in the hospital system. Now, international medtechs are starting to react, with some downscaling local operations and portfolios. Association of Research Based Medical Technologies Manufacturers president Umut Gokalp laid out the problems being faced by industry, and what action he thinks the government should take.
The Turkish government’s drive to establish domestic manufacturing for vaccines is showing tentative signs of getting off the ground. New partnerships are forming between Turkish and international partners. However, lack of local know-how is hampering progress.
Late payments of medtech bills by hospitals combined with persistently low reimbursement prices have pushed Turkish device manufacturers to the brink. But after a recent intervention from the industry, the government has finally done something to address industry’s calls for systematic and comprehensive improvement of medtech reimbursement prices.